Welcome to our dedicated page for Nautilus Biotechnology news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology stock.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) is a development stage life sciences company developing a single-molecule proteome analysis platform, and the news surrounding NAUT often centers on progress toward validating and deploying this technology. The company’s communications highlight its Iterative Mapping method, tau proteoforms assay, and collaborations with leading research institutions as key themes in its news flow.
Readers following Nautilus news can expect updates on platform development milestones, such as the successful installation and testing of the first external field evaluation unit at the Buck Institute for Research on Aging. News has described how researchers at the Buck Institute generated highly reproducible tau proteoform data from neurodegenerative disease samples and used the Nautilus Proteome Analysis Platform to explore region-specific proteoform patterns associated with disease progression.
NAUT news also covers agreements and collaborations, including an agreement with the Allen Institute focused on investigating the connection between tau protein and neurodegenerative conditions such as Alzheimer’s disease. These announcements often discuss efforts to identify novel tau proteoforms, quantify their prevalence, and characterize phosphorylation patterns that may help explain disease course.
Financial results and corporate updates are another important category of Nautilus news. The company regularly issues quarterly earnings press releases describing operating expenses, net loss, cash, cash equivalents, and investments, along with commentary on development progress and plans for its platform and Early Access Program. Investors can also find notices about upcoming earnings calls, participation in healthcare and investor conferences, and regulatory filings reported via Form 8-K.
In addition, Nautilus has announced an Early Access Program for its proteomics platform, starting with a tau proteoforms assay, which is a recurring topic in its news. These articles explain how selected researchers gain access to the Iterative Mapping method, receive support for data interpretation and analysis, and participate in custom assay development partnerships. For anyone tracking NAUT, this news page provides a centralized view of technology, collaboration, commercialization, and financial developments related to the company’s single-molecule proteomics efforts.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced that it will disclose its financial results for the first quarter of 2023 on May 2, 2023, prior to the market opening. Management will host a conference call on the same day at 5:30 a.m. PT / 8:30 a.m. ET to discuss these results, along with business developments and future outlook. This will be streamed live on the company’s website. Nautilus is focused on developing a platform for protein analysis aiming to enhance the field of proteomics and improve human health outcomes.
Nautilus Biotechnology, a leader in single-molecule protein analysis, will participate in the B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics Virtual Conference on April 6, 2023. The management will feature in a fireside chat at 10:30 a.m. Pacific Time. Investors and interested individuals can tune in to a live and archived webcast on the company’s website. Nautilus aims to revolutionize proteomics by enhancing access to the proteome, fostering significant advancements in human health. To learn more, visit www.nautilus.bio.
Nautilus Biotechnology, a life sciences company, announced the selection of three research proposals from leading institutions for its First Access Challenge. This initiative grants early access to Nautilus' innovative single-molecule protein analysis platform. The winning projects focus on:
- Therapeutics for Acute Kidney Injuries by researchers at Buck Institute.
- Pathology of Pulmonary Fibrosis conducted by Brigham Young University.
- Cancer Therapies for Glioma led by the University of Southern California.
Each team will analyze samples and receive travel stipends for conference presentations, boosting Nautilus' commitment to advancing proteomics.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its Q4 and fiscal year 2022 results, highlighting significant advancements in its proteomics platform. The company formed a strategic partnership with TGen to investigate protein targets in DIPG, a rare childhood cancer. Operating expenses increased by 26% to $63.6 million, mainly due to higher headcount and public company costs, leading to a net loss of $57.9 million. However, Q4 expenses were below peak levels, ensuring a cash runway extending into 2025. With cash reserves amounting to $313.6 million, Nautilus looks forward to a commercial launch in 2023.